Loading profile...
Dr Peter Meintjes is an experienced molecular diagnostics and genomics business leader. He is a New Zealand citizen who relocated from Boston to Dunedin to join Pacific Edge. Peter started his business career in New Zealand with Auckland-based Biomatters, a bio-informatics company. He then spent six years with Budapest-based Omixon, holding senior roles in both Hungary and the US, including three years as Chief Executive Officer, during which he presided over rapid expansion with compound annual revenue growth of more than 75%. Most recently, he served as Chief Commercial Officer at Eurofins-Transplant Genomics in Massachusetts, where he led the commercialisation of the company's suite of tests for biomarkers of organ rejection, including TruGraf, the only biomarker test for kidney transplant recipients approved for reimbursement by the Centers for Medicare & Medicaid Services. Peter was appointed CEO of Pacific Edge in January 2022, bringing extensive global diagnostics, biotechnology, and commercial leadership expertise with a track record for commercialising new and disruptive biotechnologies. He holds a PhD in biological sciences from Auckland University (2008).
PhD (Biological Sciences), University of Auckland (2008)
This profile aggregates publicly-available information from 6 source registers for the purpose of cross-platform governance and transparency research. Every fact is sourced from one of the public publications listed below; the aggregation, presentation and any analytical observations are published by NZXplorer.
If anything on this page is wrong, missing context, or warrants a formal right-of-reply, use the dispute & right-of-reply form. Our editorial floor — what we always remove on request, the search-engine indexing policy, and the Privacy Act access / correction routes — is set out on Data Principles.